These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27315470)

  • 1. Bispecific Antibodies Against HIV.
    Montefiori DC
    Cell; 2016 Jun; 165(7):1563-1564. PubMed ID: 27315470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
    Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
    J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
    Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
    Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
    Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
    PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.
    Song R; Pace C; Seaman MS; Fang Q; Sun M; Andrews CD; Wu A; Padte NN; Ho DD
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):365-373. PubMed ID: 27792681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV: Efficacy through BibNAbs.
    Flemming A
    Nat Rev Drug Discov; 2013 Sep; 12(9):666. PubMed ID: 23989794
    [No Abstract]   [Full Text] [Related]  

  • 7. Engineering multi-specific antibodies against HIV-1.
    Padte NN; Yu J; Huang Y; Ho DD
    Retrovirology; 2018 Aug; 15(1):60. PubMed ID: 30157871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
    Wu X; Guo J; Niu M; An M; Liu L; Wang H; Jin X; Zhang Q; Lam KS; Wu T; Wang H; Wang Q; Du Y; Li J; Cheng L; Tang HY; Shang H; Zhang L; Zhou P; Chen Z
    J Clin Invest; 2018 Jun; 128(6):2239-2251. PubMed ID: 29461979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.
    Huang Y; Yu J; Lanzi A; Yao X; Andrews CD; Tsai L; Gajjar MR; Sun M; Seaman MS; Padte NN; Ho DD
    Cell; 2016 Jun; 165(7):1621-1631. PubMed ID: 27315479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly Neutralizing Antibodies: Magic Bullets against HIV?
    Julg B; Alter G
    Immunity; 2016 Jun; 44(6):1253-4. PubMed ID: 27332729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
    Halper-Stromberg A; Nussenzweig MC
    J Clin Invest; 2016 Feb; 126(2):415-23. PubMed ID: 26752643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment.
    Ferrari G
    J Clin Invest; 2018 Jun; 128(6):2189-2191. PubMed ID: 29683434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing antibodies to prevent HIV-1.
    Cohen MS; Corey L
    Science; 2017 Oct; 358(6359):46-47. PubMed ID: 28983040
    [No Abstract]   [Full Text] [Related]  

  • 20. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.